On March 24, 2025, Surrozen Inc. entered into a Securities Purchase Agreement for a private placement, raising approximately $76.4 million from the sale of 6,586,415 Units, with a second tranche potentially raising an additional $98.6 million contingent on FDA clearance by October 31, 2026. Tim Kutzkey was appointed as a Class I director on March 26, 2025, with a $35,000 annual retainer and stock options.